Skip to content Skip to footer
Subscribe Now

NEWS

IQVIA and Kexing Biopharm Strengthen Strategic Collaboration to Advance Global Biosimilar Development through AI-enabled Capabilities 
 Shots:  IQVIA is expanding its collaboration with Kexing Biopharm to advance a global multi-product biosimilar development and commercialization program  As part of the collaboration, IQVIA will provide end-to-end development, regulatory, analytics, and commercialization support to accelerate Kexing’s global biosimilar expansion while maintaining high quality and scientific standards  The collaboration also integrates IQVIA’s AI-enabled clinical trial capabilities to streamline protocol design, site selection,…
May 13, 2026
Rigel Signs ~$445M Licensing Pact with Arvinas and Pfizer for Veppanu
Shots: Rigel has entered into an exclusive, global license agreement with Arvinas & Pfizer to develop, manufacture & commercialize FDA-approved Veppanu (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. As per the deal, Rigel will pay Arvinas & Pfizer $70M upfront, $15M in upon completion of transition activities, & ~$320M in milestones plus tiered royalties…
May 12, 2026
Tolion Health AI Launches AI-Powered Tolion Brain Coach App for Brain Health, Longevity, and Prevention of Alzheimer’s Disease
Shots: Tolion Health AI has launched Tolion Brain Coach, a new App within its Brain Health Platform designed to deliver personalized, preventive, & predictive insights for cognitive health using AI-driven analytics & wearable-device data Platform leverages Tolion’s Knowledge Engine & Brain Score to generate tailored recommendations aimed at strengthening cognitive resilience & reducing neurodegenerative disease…
May 12, 2026
Exero Medical Reports the Trial Data on xBar Monitoring System for Early Detection of Colorectal Surgery Complications
Shots: Exero Medical has reported clinical trial data assessing xBar monitoring system to detect post-operative anastomotic leaks in colorectal resection surgery pts (n=222) Study showed that the xBar system detected post-operative anastomotic leaks in colorectal resection pts earlier than standard clinical practice, achieving 100% sensitivity & 88% specificity by post-operative day 3 & identifying leaks…
May 12, 2026
Roche
Roche’ Elecsys pTau217 Test Receives the European CE Mark Approval to Rule in or Rule Out Alzheimer’s-Related Amyloid Pathology
Shots: Roche has received CE Mark for Elecsys pTau217 to measure the phosphorylated Tau (pTau) 217 protein to help rule in or rule out Alzheimer’s-related amyloid pathology CE Mark was backed by retrospective real-world studies in early-stage Alzheimer’s pts, incl. Subjective Cognitive Decline, Mild Cognitive Impairment, & Mild Dementia, where individuals experience memory changes but…
May 12, 2026
BMS Partners with Hengrui Pharma in a Potential ~$15.2B Deal to Advance 13 Early-Stage Programs Across Oncology, Hematology, and Immunology
Shots: BMS has partnered with Hengrui to advance 13 early-stage programs, incl. 4 Hengrui onco/hemo assets, 4 BMS immunology assets, and 5 jointly discovered & developed candidates; expected to close in Q3’26 Hengrui will lead early clinical development, while BMS gains ex-China rights to Hengrui-originated assets & Hengrui will secure exclusive Greater China rights to…
May 12, 2026
Load more